Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02081196 · ClinicalTrials.gov registry record · NA

CoolSculpting of the Flank With Alternate Treatment Parameters

A NA study, sponsored by Zeltiq Aesthetics.

Completed
Registry status
NA
Development phase
45
Enrollment target

NCT02081196: Completed NA study, sponsored by Zeltiq Aesthetics.

NCT02081196 is a NA study that has completed, run by Zeltiq Aesthetics. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02081196, a NA study, has completed, sponsored by Zeltiq Aesthetics.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction with an alternative treatment parameter.

Primary Outcome

The number of device- or procedure-related adverse events will be tabulated. Adverse event reports are collected throughout the study from enrollment through the 16 week follow-up visit. The investigator determines if there is a relationship between the event and the study device or procedure.

Interventions

  • DEVICE The Zeltiq CoolSculpting System

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2014-02-18
Est. Completion 2014-06-27
Phase NA
Zeltiq Aesthetics

30 total trials

What the finished NCT02081196 record still lists

NCT02081196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which The Zeltiq CoolSculpting System is the first listed.

NCT02081196 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02081196 about?

NCT02081196 is a clinical study titled "CoolSculpting of the Flank With Alternate Treatment Parameters". The purpose of this study is to evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction with an alternative treatment parameter.

What is the current status of trial NCT02081196?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2014-02-18. Estimated completion is 2014-06-27.

What interventions are being tested in trial NCT02081196?

The interventions under investigation include: The Zeltiq CoolSculpting System (DEVICE).

Who is sponsoring clinical trial NCT02081196?

This trial is sponsored by Zeltiq Aesthetics, which has 30 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02081196's enrollment target sits among peer trials

45 1411th of 2000 higher than 578 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02081196, the US trial registry maintained by the National Library of Medicine. NCT02081196 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.